HOME > BUSINESS > Sun Pharma selects Samsung to manufacture psoriasis drug

Sun Pharma selects Samsung to manufacture psoriasis drug

Sun Pharma said it has inked a long-term agreement with Samsung BioLogics under which the Korean company will manufacture Tildrakizumab, a potential treatment for plaque psoriasis, for the Indian company.

Plaque psoriasis is an autoimmune condition which results in patches of thick, red, scaly skin.

The approximate value of the contract will be US$ 55.5 million, other financial details of the agreement are confidential, it said.

Commenting on its agreement with Samsung BioLogics, Mr Kirti Ganorkar, Global Head – Portfolio Management & Business Development, Sun Pharma said, “Samsung BioLogics is a globally renowned CMO. Through this partnership we will leverage Samsung’s manufacturing knowledge and world class quality systems to provide high quality products for the Tildrakizumab pipeline.”

TH Kim, President and CEO of Samsung BioLogics said: “Our collaboration with Sun Pharma is an important milestone for Samsung as it is a testament of our ability to provide reliable supply through its GMP-certified manufacturing facility to pharmaceutical companies, which aim to expand their global market.”

The filing for the investigational biologic has been accepted for review by the U.S. Food and Drug Administration (FDA) (May 2017) and the European Medicines Agency (EMA) (March 2017), the Indian company said.

Tildrakizumab is an investigational humanized, anti-IL-23p19 monoclonal antibody designed to selectively block the cytokine IL-23. With this precise targeting, tildrakizumab has the potential to help control the pathogenic cells responsible for the inflammatory process of psoriasis with limited impact on the rest of the immune system, Sun Pharma said.

“Phase-3 tildrakizumab data provide further evidence for the role of the IL-23 pathway in helping to control the inflammatory process of psoriasis,” it said.

The regulatory filings associated with tildrakizumab have been accepted for review by the FDA and EMA.

Follow ULTRA.news
Strides Shasun says Eris deal to help reprioritize business, lower debt Pharma major Strides Shasun said it agreed to sell its India branded generics business to Eris LifeSciences Limited for Rs 500 cr in cash."This transaction is the outcome of the company's portfolio reprioritization, to focus more sharply on larger regulated markets," it said...
Zydus gets nod for anti-inflammation drug in the US Pharma major Zydus Cadila said it received final approval from the USFDA to market an anti-inflammatory injection Ethacrynate Sodium in the US.The drug is used to decrease the Swelling (edema) caused by various disease conditions such as liver disease, kidney disease, conges...
Cipla launches ashtha inhaler therapy in the US Pharma giant Cipla Ltd said it received final approval for launching a generic version of Astrazeneca’s Pulmicort inhalation suspension for pediatric asthma in the US.The product is available for shipping immediately, Cipla said.Pulmicort Respules and generic equivalent...
Suven Life Sciences gets patents in USA, India and Hong Kong Pharma company Suven Life Sciences Ltd said it received new patents in India, USA and Hong Kong for neurological drugs.The patents -- one each in Hong Kong and the US and a couple in India -- are valid through 2032, 2030 and 2034."The granted claims of the patents include...
Zydus Cadila has an excellent quarter in Q2, PAT up 33% Pharma giant Zydus Cadila reported excellent numbers for the September quarter, led by rising US revenue that lifted its margins and profits.For the second quarter ended September 30, 2017, Zydus Cadila reported Earnings before Interest, Depreciation and Tax (EBIDTA) of Rs. 8...
Royal Orchid Hotels inks marketing tie-up with UK’s Bespoke Hotels Royal Orchid Hotels said it had tied up with Bespoke Hotels of the UK to market each others' properties to their customers.Bespoke manages over 200 hots with 9,500 hotel rooms, 8,000 employees and £815 million of assets."Royal Orchid now has the ability to offer its gues...
Alembic Pharma buys US-based generics manufacturer Alembic Pharmaceuticals said it bought New Jersey-based generic drug developer Orit Laboratories LLC, which will bring seven approved generics and four applications with it.Orbit has "a team of eight highly experienced scientists," Alembic said, adding that the firm focuses ...
Lupin Q2 sales down 8%, PAT falls 31.3% Pharma major Lupin reported an 8% fall in Q2 revenue to Rs. 3,952 cr.Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) for the quarter fell by 13% to 927 cr.Net profit was also down by 31.3% at Rs 455 cr in in the September quarter. The profit was high...
Cipla gets USFDA nod to launch kidney drug in the US Pharma giant Cipla said it received final approval to market a generic version of Genzyme’s kidney drug Renvela Tablets in the US.Renvela Tablets had US sales of approximately $1.85 billion for the 12-month period ending August 2017, according to IMS Health.The approval...
Suven Life Sciences gets patent for neuro drug Suven Life Sciences Ltd said it was granted a patent by New Zealand authorities for "a class of selective 5-HT4 compounds" that are being developed to treat neurodegenerative diseases.The compounds are being explored for use in cases of Alzheimer’s disease, Attention deficie...
USFDA returns Mylan-Biocon’s drug application for more data The U.S. Food and Drug Administration has sought more data before approving a chemotherapy compound submitted by Mylan and jointly developed by Biocon.The agency issued a 'complete response letter'. Such letters are issued when an FDA review an FDA review finds that an appli...
Mitashi launches 55-inch curved TV with Samsung 4K panel @Rs 80k Mitashi, the Mumbai-based electronics brand known for its value-for-money offerings, launched a 55-inch curved 4K TV with a Samsung panel at Rs 79,990 in India.The device is the cheapest such television in the Indian market.Its closest competitor is the Samsung 49Ku6300,...
PREMIUM PHONES: OnePlus has 57% market share online, Samsung 4% OnePlus, the sister company of Vivo and Oppo, totally dominates the online market for premium handsets with a 57% market share compared to just 4% for Samsung, the Chinese company said, quoting numbers from IDC.The numbers are only for online sales, and do not include data f...
NATCO Pharma to sell multiple sclerosis drug in USA via Mylan NATCO Pharma Limited said it the US Food and Drug Administration approved the generic drug application filed by its marketing partner Mylan for injections used in the treatment of multiple sclerosis, a chronic inflammatory disease of the central nervous system.The drug, Glat...
Cyient ties up with US start-up to incorporate AI tech in power solution Mumbai-based IT services provider Cyient said it has signed an agreement to incorporate machine learning meter and voltage signature technology from US-based startup Elpis in its solutions for power utilities."Through this agreement, Cyient and Elpis will jointly pursue util...
Infosys to deliver private cloud solution based on Suse Linux and Openstack IT services provider Infosys said it now offers a private cloud solution built using SUSE Linux and Openstack.The solution will make use of Openstack cloud and datacenter solutions developed by Germany-based Micro Focus SUSE.Infosys and Micro Focus SUSE have jointly inve...
Vivimed pharma unit gets Rs 270 cr investment from OrbiMed fund Pharmaceuticals and specialty chemicals maker Vivimed Labs said investment firm OrbiMed will invest $42.5 mn (Rs 270 cr) into its active pharmaceutical ingredients business.The investment will be into Vivimed Labs Mascarene Ltd, which is in turn the holding entity of the com...
L&T Technology Services to co-develop solutions with Intel unit L&T Technology Services, the engineering services arm of the construction conglomerate, will co-develop industrial solutions with Intel subsidiary Wind River, which works in the emerging domain of Internet of Things.Under the partnership L&T Technology Services will "validat...
HTC U11 smartphone to get a price cut under Flipkart’s Big Billion Days sale HTC U11, the Taiwanese company's come-back model, is all set to get an unspecified price cut under Flipkart's Big Billion Days mobile sale that starts tomorrow at midnight.The online portal is teasing a price cut without revealing the extent of the cut.The current price ...
Glenmark to launch Desonide topical ointment in US Glenmark Pharmaceuticals Inc said it has got the go-ahead to launch the generic version of Perrigo's anti-inflammation ointment Desonide Ointment in the US.Desonide Ointment, 0.05% had annual sales of approximately $23.4 million for the 12 month period ending July 2017, acco...